Page last updated: 2024-11-05

3-hydroxy-2-naphthoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Hydroxy-2-naphthoic acid is a white to yellowish crystalline solid that is a key intermediate in the synthesis of various dyes, pharmaceuticals, and other organic compounds. It is synthesized through several methods, including the Kolbe-Schmitt reaction and the reaction of 2-naphthol with carbon dioxide. It is known to exhibit anti-inflammatory and antibacterial activities, and has been studied for its potential use in treating various ailments. It is also used in the production of pigments and resins. The compound is studied due to its versatility as a building block for various synthetic compounds and its potential medicinal properties. The compound is also of interest in the field of organic synthesis due to its unique structure and reactivity.'

3-hydroxy-2-naphthoic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Bonagenus[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID7104
CHEMBL ID229301
CHEBI ID80383
SCHEMBL ID6460
MeSH IDM0075994

Synonyms (95)

Synonym
3-hydroxynaphthalene-2-carboxylic acid
3-hydroxy-2-naphthoic acid
developer bon
3-naphthol-2-carboxylic acid
bona
2-naphthoic acid, 3-hydroxy-
2-hydroxy-3-naphthoic acid
.beta.-oxynaphthoic acid
bon acid
3-hydroxy-2-naphthalenecarboxylic acid
miketazol developer ons
nsc3719
nsc-3719
.beta.-hydroxynaphthoic acid
92-70-6
wln: l66j cvq dq
3-hydroxy-.beta.-naphthoic acid
BON ,
b.o.n. acid
c.i. developer 20
2-naphthol-3-carboxylic acid
2-naphthalenecarboxylic acid, 3-hydroxy-
naphthol b.o.n.
2-hydroxy-3-naphthalenecarboxylic acid
inchi=1/c11h8o3/c12-10-6-8-4-2-1-3-7(8)5-9(10)11(13)14/h1-6,12h,(h,13,14
ccris 2298
3-hydroxy-2-naphthoesaeure
beta-oxynaphthoic acid
hsdb 5278
developer 8
beta-hydroxynaphthoic acid
c.i. developer 20 (obs.)
brn 0744100
beta-naphthoic acid, 3-hydroxy-
3-hydroxy-beta-naphthoic acid
kyselina 3-hydroxy-2-naftoova [czech]
einecs 202-180-8
ci developer 20
ai3-00894
naphthol bon
nsc 3719
c.i. developer 8
OPREA1_703066
3-hydroxy-2-naphthoic acid, 98%
NCGC00164007-01
CHEMBL229301 ,
chebi:80383 ,
bdbm50219485
H0281
AKOS000119000
NCGC00164007-02
ST053520
kyselina 3-hydroxy-2-naftoova
unii-c7s9d784hx
4-10-00-01184 (beilstein handbook reference)
c7s9d784hx ,
ec 202-180-8
dtxsid3026560 ,
NCGC00256979-01
dtxcid406560
cas-92-70-6
tox21_303283
tox21_201550
NCGC00259099-01
BBL011509
STL146624
BP-13161
FT-0612537
FS-2401
AM20060754
SCHEMBL6460
3-hydroxy-2naphthoic acid
3-hydroxy-naphthalene-2-carboxylic acid
2-hydroxy-naphthalene-3-carboxylic acid
3-hydroxy-2-naphtoic acid
2-hydroxynaphthalene-3-carboxylic acid
3-hydroxy-2-napthoic acid
3-hydroxy-2-naphthalenecarboxylic acid [hsdb]
3-hydroxy-2-naphthoic acid [mi]
3-hydroxynaphthalenecarboxylic acid-(2)
2-hydroxy-3-napthoic acid
W-100276
CS-W016820
3-hydroxy-2-naphthoicacid
mfcd00004103
AC-10102
sr-01000944727
SR-01000944727-1
3-hydroxy-2-naphthoic acid, technical, >=95% (t)
D77800
bzj ,
Q27149406
EN300-21471
F1908-0111
Z104498570
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthoic acidAn aromatic carboxylic acid that consists of a naphthalene skeleton substituted by one or more carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency33.52390.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency15.34600.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency5.40950.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency45.28930.000221.22318,912.5098AID743035; AID743036; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency9.61960.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.80810.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency31.30380.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency60.69570.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency48.16560.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency42.50200.000229.305416,493.5996AID588514; AID743069; AID743075; AID743077; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency44.66840.001024.504861.6448AID588534
caspase-3Homo sapiens (human)Potency9.61960.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency47.17430.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency32.38480.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.10160.000323.4451159.6830AID743065
histone deacetylase 9 isoform 3Homo sapiens (human)Potency24.75960.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency48.55770.000627.21521,122.0200AID720636
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)1,000.00000.05373.075710.0000AID638470
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)1,000.00000.00053.49849.7600AID289410
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1606677Inhibition of hexahistidine-SUMO tagged Mycobacterium tuberculosis InhA expressed in Escherichia coli BL21(DE3) at 2 mM preincubated for 10 mins with NADH before addition of 2-trans-octanoyl-CoA as substrate and measured after 20 mins by NADH oxidation de2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Fragment-Based Design of
AID1606675Binding affinity to hexahistidine-SUMO tagged Mycobacterium tuberculosis InhA expressed in Escherichia coli BL21(DE3) at 1 mM in presence of 0.5 mM NAD+ by CPMG NMR analysis2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Fragment-Based Design of
AID1606676Binding affinity to hexahistidine-SUMO tagged Mycobacterium tuberculosis InhA expressed in Escherichia coli BL21(DE3) at 1 mM in presence of 0.5 mM NAD+ by WaterLOGSY NMR analysis2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Fragment-Based Design of
AID1606673Binding affinity to hexahistidine-SUMO tagged Mycobacterium tuberculosis InhA expressed in Escherichia coli BL21(DE3) assessed as increase the melting temperature at 5 mM in presence of 1 mM NAD+ by differential scanning fluorimetry2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Fragment-Based Design of
AID1606674Binding affinity to hexahistidine-SUMO tagged Mycobacterium tuberculosis InhA expressed in Escherichia coli BL21(DE3) at 1 mM in presence of 0.5 mM NAD+ by NMR spectroscopy2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Fragment-Based Design of
AID289410Inhibition of PTP1B2007Bioorganic & medicinal chemistry, Oct-15, Volume: 15, Issue:20
Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs.
AID638470Inhibition of His-tagged recombinant human IDO1 expressed in Escherichia coli using tryptophan as substrate by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Feb-01, Volume: 20, Issue:3
Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (26.32)18.7374
1990's0 (0.00)18.2507
2000's5 (26.32)29.6817
2010's7 (36.84)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.33 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]